Ethical issues in rheumatology clinical trials

Nature Clinical Practice Rheumatology

Volumn 4, Issue 7, 2008, Pages 356-363

  Sugarman, Jeremy ^a   Bingham III, Clifton O ^b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Arthritis Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DENOSUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO;

CLINICAL RESEARCH; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; EXPERIMENTAL DESIGN; GASTROINTESTINAL TOXICITY; HUMAN; INFORMED CONSENT; LONG TERM CARE; METHODOLOGY; OSTEOARTHRITIS; OUTCOME ASSESSMENT; PATIENT CARE; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; RESEARCH ETHICS; REVIEW; RHEUMATOID ARTHRITIS; RHEUMATOLOGY;

ANTIBODIES, MONOCLONAL; CLINICAL TRIALS AS TOPIC; ETHICS, RESEARCH; GENE THERAPY; HUMANS; INFORMED CONSENT; OSTEOARTHRITIS; OUTCOME ASSESSMENT (HEALTH CARE); PRODUCT SURVEILLANCE, POSTMARKETING; RHEUMATIC DISEASES; RHEUMATOLOGY;

EID: 47149083731     PISSN: 17458382     EISSN: 17458390     Source Type: Journal    
DOI: 10.1038/ncprheum0829     Document Type: Review

References (38)

1. Kavanaugh A (2005) Ethical and practical issues in conducting clinical trials in psoriasis and psoriatic arthritis. Ann Rheum Dis 64 46-48
2. Sugarman J (2002) Ethics in the design and conduct of clinical research. Epidemiol Rev 24: 54-58
3. Bodenheimer T (2000) Uneasy alliance - clinical investigators and the pharmaceutical industry. N EngI J Med 342: 1539-1544
4. van Dongen H et al. (2007) Effidacy of methotrexate treatment in patients with probable rheumatold arthritis: A double-blind, randomized, placebo-controlled trial. Arthritis Rheum 56: 1424-1432
5. Simon AE et al. (2007) Preventive misconception: Its nature, presence, and ethical implications for research. Am J Prevent Med 32: 370-374
6. Psaty BM and Korn D (2007) Congress responds to the IOM drug safety report - in full. JAMA 298, 2185-2187
7. Baldini C et al. (2005) From clinical trials to the bedside: How can we treat patients with rheumatoid arthritis and concurrent morbidities who are generally excluded from randomised controlled clinical trials? Clin Exp Rheumatol 23: 893-904
8. Zink A et al. (2006) Effectiveness of tumer necrosis factor inhibitors in rheumatoid arthritis In an observational cohort study: comparison of patients according to their eligibility for major randomized clinical trials. Arthritis Rheum 54: 3399-3407
9. Dixon WG et al. (2007) Serious infection following anti-tumor necrosis factor alpha therapy in patients with rheumatoid arthritis: lessons from interpreting data from observational studies. Arthritis Rheum 56: 2896-2904
10. Singh G et al. (1996) Gastrointestinal tract complications of nonsteroidal anti-inflammatory drug treatment in rheumatoid arthritis: A prospective observational cohort study. Arch Intern Med. 158 1530-1536
11. Fries JF et al. (1993) The relative toxicity of disease-modifying antirheumatic drugs. Arthritis Rheum 36: 297-306
12. Schneeweiss S et al. (2007) Anti-tumor necrosis factor alpha therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis. Arthritis Rheum 56: 1754-1764
13. Wolfe F and Michaud K (2004) Lymphoma in rheumatoid arthritis: The effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum 50: 1740-1751
14. Keane J et al. (2001) Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 345: 1098-1104
15. Furberg CD et al. (2006) The FDA and drug safety: A proposal for sweeping changes. Arch Intern Med 166: 1938-1942
16. Kessler DA et al. (1994) Therapeutic-class wars - drug promotion in a competitive marketplace. N Engl J Med 331: 1350-1353
17. La Puma J (1995) Physician rewards for postmarketing surveillance (seeding studies) in the US. Pharmacoeconomics 7: 187-190
18. Psaty BM and Rennie D (2006) Clinical trial investigators and their prescribing patterns: Another dimension to the relationship between physician investigators and the pharmaceutical industry. JAMA 295: 2787-2790.
19. Al-Khatib SM et al. (2001) Placebo-controls in short-term clinical trials of hypertension. Science 292: 2013-2015
20. Lovell DJ et al. (2000) Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med 342: 763-769
21. Boers M (2003) Add-on or step-up trials for new drug development in rheumatoid arthritis: A new standard? Arthritis Rheum 48: 1481-1483
22. Felson DT et al. (2007) Rationale and strategies for reevaluating the ACR20. J Rheumatol 34: 1184-1187
23. American College of Rheumatolorgy Ad Hoc Committee on Systemic Lupus Erythematosus Response Criteria (2004) The American College of Rheumatology response criteria for systemic lupus erythematosus clinical trials: Measures of overall disease activity. Arthritis Rheum 50: 3418-3426
24. Bingham CO III et al. (2006) Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee: Results of the two-year multinational knee osteoarthritis structural arthritis study. Arthritis Rheum 11 3494-3507
25. Abadie E et al. (2004) Recommendations for the use of new methods to assess the efficacy of disease-modifying drugs in the treatment of osteoarthritis. Osteoarthritis Cartilage 12: 263-268
26. van der Heijde D et al. (2007) Denosumab inhibits RANKL, reducing progression of the total sharp score and bone erosions in patients with rheumatoid arthritis: 12-month X-ray results [abstract #698]. Presented at the American College of Rheumatology National Scientific Meeting: 2007 November 6-11, Boston, MA
27. Sugarman J et al. (2005) Evaluating the quality of informed consent. Clin Trials 2: 34-41
28. Criscione L et al. (20030) Informed consent in a clinical trial of a new treatrrient for rheumatoid arthritis. Arthritis Rheum 49 361-367
29. King NM (1999) Rewriting the "points to consider": The ethical impact of guidance document language. Hum Gene Ther 10: 133-139.
30. Taylor HA et al. (2007) Formative research in clinical. trial development: Attitudes of patients with arthritis in enhancing prevention trials. Ann Rheum Dis 66: 542-544
31. Lavori PW (1999) Improving informed consent in clinical trials: A duty to experiment. Control Clin Trials 20: 187-193
32. Fries JF and Krishnan E (2004) Equipoise, design bias, and randomized controlled trials: The elusive ethics of new drug development. Arthritis Res Ther 6: R250-R255
33. Kahn JP et al. (1998) Beyond Consent: Seeking Justice in Research. New York: Oxford University Press
34. Suntharalingam G et al. (2006) Cytokine Storm in the Phase I trial of monoclonal antibody TGN1412. N Engl J Med 355: 1018-1028
35. Sugarman J and Levine C (2006) Risk in drug trials. Lancet 368 2205.
36. Levine C et al. for the Consortium to Examine Clinical Research Ethics (2004) "Special scrutiny": A targeted form of research protocol review. Ann Intern Med 140: 220-223
37. Hampton T (2008) Arthritis gene therapy trial resumes. JAMA 299 28
38. Boissier MC (2001) Ethical aspects of gene therapy in rheumatology. Joint Bone Spine 68: 109-111.